Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 20.07
NAS:BIOL's Cash to Debt is ranked higher than
69% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.56 vs. NAS:BIOL: 20.07 )
Ranked among companies with meaningful Cash to Debt only.
NAS:BIOL' s Cash to Debt Range Over the Past 10 Years
Min: 0.08  Med: 3.54 Max: No Debt
Current: 20.07
Equity to Asset 0.53
NAS:BIOL's Equity to Asset is ranked lower than
59% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. NAS:BIOL: 0.53 )
Ranked among companies with meaningful Equity to Asset only.
NAS:BIOL' s Equity to Asset Range Over the Past 10 Years
Min: -0.35  Med: 0.42 Max: 0.91
Current: 0.53
-0.35
0.91
Interest Coverage N/A
NAS:BIOL's Interest Coverage is ranked higher than
72% of the 138 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 40.78 vs. NAS:BIOL: N/A )
Ranked among companies with meaningful Interest Coverage only.
NAS:BIOL' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: N/A Max: N/A
Current: N/A
F-Score: 4
Z-Score: -2.24
M-Score: -2.58
WACC vs ROIC
11.63%
-117.44%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -30.31
NAS:BIOL's Operating margin (%) is ranked lower than
76% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.16 vs. NAS:BIOL: -30.31 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:BIOL' s Operating margin (%) Range Over the Past 10 Years
Min: -43.83  Med: -13.5 Max: -4.41
Current: -30.31
-43.83
-4.41
Net-margin (%) -30.85
NAS:BIOL's Net-margin (%) is ranked lower than
74% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.53 vs. NAS:BIOL: -30.85 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:BIOL' s Net-margin (%) Range Over the Past 10 Years
Min: -45.84  Med: -12.51 Max: -5.33
Current: -30.85
-45.84
-5.33
ROE (%) -63.48
NAS:BIOL's ROE (%) is ranked lower than
85% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.19 vs. NAS:BIOL: -63.48 )
Ranked among companies with meaningful ROE (%) only.
NAS:BIOL' s ROE (%) Range Over the Past 10 Years
Min: -492.46  Med: -65.55 Max: -21.68
Current: -63.48
-492.46
-21.68
ROA (%) -36.25
NAS:BIOL's ROA (%) is ranked lower than
82% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. NAS:BIOL: -36.25 )
Ranked among companies with meaningful ROA (%) only.
NAS:BIOL' s ROA (%) Range Over the Past 10 Years
Min: -59.62  Med: -20.77 Max: -9.89
Current: -36.25
-59.62
-9.89
ROC (Joel Greenblatt) (%) -131.20
NAS:BIOL's ROC (Joel Greenblatt) (%) is ranked lower than
79% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.92 vs. NAS:BIOL: -131.20 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:BIOL' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -445.37  Med: -125.5 Max: -36.01
Current: -131.2
-445.37
-36.01
Revenue Growth (3Y)(%) -22.40
NAS:BIOL's Revenue Growth (3Y)(%) is ranked lower than
89% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. NAS:BIOL: -22.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:BIOL' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -27.8  Med: 11.4 Max: 104.2
Current: -22.4
-27.8
104.2
EBITDA Growth (3Y)(%) 68.80
NAS:BIOL's EBITDA Growth (3Y)(%) is ranked higher than
96% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. NAS:BIOL: 68.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:BIOL' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -47.3  Med: -4.7 Max: 92.1
Current: 68.8
-47.3
92.1
EPS Growth (3Y)(%) 51.80
NAS:BIOL's EPS Growth (3Y)(%) is ranked higher than
91% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.00 vs. NAS:BIOL: 51.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:BIOL' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -53.1  Med: -3.4 Max: 142.2
Current: 51.8
-53.1
142.2
» NAS:BIOL's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

BIOL Guru Trades in Q3 2015

Mario Gabelli 91,455 sh (unchged)
» More
Q4 2015

BIOL Guru Trades in Q4 2015

Mario Gabelli 91,455 sh (unchged)
» More
Q1 2016

BIOL Guru Trades in Q1 2016

Mario Gabelli 91,455 sh (unchged)
» More
Q2 2016

BIOL Guru Trades in Q2 2016

Charles Brandes 23,093 sh (New)
Mario Gabelli 91,455 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with BIOL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:AMEX:BVX, NAS:HBIO, OTCPK:TDMMF, NAS:DSCI, NAS:PLSE, AMEX:RVP, NAS:HNSN, NAS:SIEN, NAS:LAKE, NAS:ATEC, AMEX:INFU, NAS:EKSO, AMEX:MLSS, NAS:LENS, OTCPK:PSDLF, OTCPK:TSNLF, AMEX:TRXC, NAS:CASM, AMEX:LBMH, AMEX:ISR » details
Traded in other countries:BTH.Germany,
Biolase Inc is a biomedical company that develops, manufactures, and markets lasers in dentistry and medicine and also markets and distributes dental imaging equipment.

Biolase Inc was originally formed as Societe Endo Technic, SA ("SET") in 1984 in Marseilles, France. In 1987, SET merged into Pamplona Capital Corp., a public holding company incorporated in Delaware. In 1994, it changed its name to BIOLASE Technology, Inc. and to BIOLASE, Inc. ("BIOLASE") in 2012. The Company is a biomedical company that develops, manufactures, and markets lasers in dentistry and medicine and also markets and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intra-oral scanners, and in-office, chair-side milling machines and three-dimensional ("3-D") printers; products that are focused on technologies that advance the practice of dentistry and medicine. Its proprietary dental laser systems allows dentists, periodontists, endodontists, oral surgeons, and other specialists to perform a dental procedures, including cosmetic, restorative, and complex surgical applications. Its systems are designed to provide performance for many types of dental procedures with less pain and faster recovery times than are generally achieved with drills, scalpels, and other conventional instruments. The Company has clearance from the U.S. Food and Drug Administration (the "FDA") to sell its laser systems in the United States and also have the necessary registration to sell its laser systems in Canada, the European Union, and various other international markets. Its licensed dental imaging equipment and other related products are designed to improve diagnoses, applications, and procedures in dentistry and medicine. It offers two categories of laser system products: WaterLase systems and Diode systems. Its WaterLase system, uses a patented combination of water and laser energy to perform most procedures currently performed using dental drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. It currently has approximately 180 issued and 120 pending U.S. and international patents, the majority of which are related to WaterLase technology and dental and medical lasers.

Ratios

vs
industry
vs
history
P/B 5.38
BIOL's P/B is ranked lower than
76% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.23 vs. BIOL: 5.38 )
Ranked among companies with meaningful P/B only.
BIOL' s P/B Range Over the Past 10 Years
Min: 0.87  Med: 6.51 Max: 43.33
Current: 5.38
0.87
43.33
P/S 2.00
BIOL's P/S is ranked higher than
58% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.13 vs. BIOL: 2.00 )
Ranked among companies with meaningful P/S only.
BIOL' s P/S Range Over the Past 10 Years
Min: 0.13  Med: 1.53 Max: 5.36
Current: 2
0.13
5.36
Current Ratio 1.91
BIOL's Current Ratio is ranked lower than
65% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.46 vs. BIOL: 1.91 )
Ranked among companies with meaningful Current Ratio only.
BIOL' s Current Ratio Range Over the Past 10 Years
Min: 0.63  Med: 1.49 Max: 8.29
Current: 1.91
0.63
8.29
Quick Ratio 1.15
BIOL's Quick Ratio is ranked lower than
70% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.64 vs. BIOL: 1.15 )
Ranked among companies with meaningful Quick Ratio only.
BIOL' s Quick Ratio Range Over the Past 10 Years
Min: 0.34  Med: 1.08 Max: 7.75
Current: 1.15
0.34
7.75
Days Inventory 145.39
BIOL's Days Inventory is ranked lower than
63% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.57 vs. BIOL: 145.39 )
Ranked among companies with meaningful Days Inventory only.
BIOL' s Days Inventory Range Over the Past 10 Years
Min: 86.85  Med: 126.99 Max: 158.88
Current: 145.39
86.85
158.88
Days Sales Outstanding 79.65
BIOL's Days Sales Outstanding is ranked lower than
75% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.25 vs. BIOL: 79.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIOL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 21.23  Med: 66.93 Max: 79.65
Current: 79.65
21.23
79.65
Days Payable 78.30
BIOL's Days Payable is ranked higher than
66% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 48.01 vs. BIOL: 78.30 )
Ranked among companies with meaningful Days Payable only.
BIOL' s Days Payable Range Over the Past 10 Years
Min: 66.88  Med: 85.18 Max: 103.46
Current: 78.3
66.88
103.46

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -22.00
BIOL's 3-Year Average Share Buyback Ratio is ranked lower than
82% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.10 vs. BIOL: -22.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BIOL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.3  Med: -5 Max: -0.5
Current: -22
-22.3
-0.5

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 8.70
BIOL's Price/Net Current Asset Value is ranked lower than
53% of the 116 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.50 vs. BIOL: 8.70 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BIOL' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.73  Med: 16.94 Max: 233.5
Current: 8.7
2.73
233.5
Price/Tangible Book 6.21
BIOL's Price/Tangible Book is ranked lower than
66% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.58 vs. BIOL: 6.21 )
Ranked among companies with meaningful Price/Tangible Book only.
BIOL' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.23  Med: 13.54 Max: 149.17
Current: 6.21
2.23
149.17
Price/Median PS Value 1.32
BIOL's Price/Median PS Value is ranked lower than
68% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.18 vs. BIOL: 1.32 )
Ranked among companies with meaningful Price/Median PS Value only.
BIOL' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.27  Med: 1.98 Max: 46.13
Current: 1.32
0.27
46.13
Earnings Yield (Greenblatt) (%) -15.86
BIOL's Earnings Yield (Greenblatt) (%) is ranked lower than
82% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.90 vs. BIOL: -15.86 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BIOL' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -121.54  Med: 1.8 Max: 2.3
Current: -15.86
-121.54
2.3

More Statistics

Revenue (TTM) (Mil) $50.57
EPS (TTM) $ -0.26
Beta1.28
Short Percentage of Float7.66%
52-Week Range $0.60 - 1.98
Shares Outstanding (Mil)58.26
» More Articles for NAS:BIOL

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: Biolase, AES Corporation, FireEye Nov 16 2015 

More From Other Websites
ETF’s with exposure to BIOLASE, Inc. : September 26, 2016 Sep 26 2016
BIOLASE Names Holger Arens Vice President, Managing Director EMEA Sep 22 2016
BIOLASE Names Holger Arens Vice President, Managing Director EMEA Sep 22 2016
BIOLASE Enters into Clinical Research Agreement with McGuire Institute for Landmark Laser Perio... Sep 12 2016
BIOLASE Enters into Clinical Research Agreement with McGuire Institute for Landmark Laser Perio... Sep 12 2016
ETF’s with exposure to BIOLASE, Inc. : August 29, 2016 Aug 29 2016
BIOLASE, INC Files SEC form 8-K, Unregistered Sale of Equity Securities, Material Modification to... Aug 08 2016
BIOLASE, INC Financials Aug 06 2016
BIOLASE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD... Aug 02 2016
BIOLASE, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 01 2016
Q2 2016 BIOLASE Inc Earnings Release - After Market Close Aug 01 2016
BIOLASE Reports 2016 Second Quarter and Six-Month Results Aug 01 2016
BIOLASE to Raise $10 Million from Institutional and Individual Investors in Convertible Preferred... Aug 01 2016
Biolase reports 2Q loss Aug 01 2016
Biolase reports 2Q loss Aug 01 2016
BIOLASE Reports 2016 Second Quarter and Six-Month Results Aug 01 2016
BIOLASE to Raise $10 Million from Institutional and Individual Investors in Convertible Preferred... Aug 01 2016
BIOLASE® to Host 2016 Second Quarter Financial Results Conference Call on August 1 Jul 25 2016
BIOLASE® to Host 2016 Second Quarter Financial Results Conference Call on August 1 Jul 25 2016
ETF’s with exposure to BIOLASE, Inc. : June 23, 2016 Jun 23 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)